Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Rho GTPase-activating protein 23 (ARHGAP23) is an intracellular enzyme that functions as a GTPase activator for members of the Rho family of small GTPases, notably including RhoA and Cdc42. By stimulating the intrinsic GTPase activity of these small G-proteins, ARHGAP23 inactivates them, thus downregulating signaling pathways that control cytoskeletal organization, cell morphology, and migration. ARHGAP23 contains conserved protein domains—PDZ, pleckstrin homology, and RhoGAP—that are important for substrate recognition and protein-protein interactions. Its activity is important for organizing the actomyosin network and confining cell protrusions, with functional implications in tissue development, neuronal signaling, and cancer progression
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Rho GTPase-activating protein 23 (ARHGAP23).